Co-Prescribing for PMAD Patients in Therapy: A Framework

Why Combined Treatment Is the Standard

For moderate-to-severe PMADs, the evidence consistently supports combined treatment: medication plus therapy produces better outcomes than either modality alone. This is not a clinical debate -- it is the established recommendation in ACOG, APA, and PSI clinical guidelines.

In practice, combined treatment usually means a prescriber managing the pharmacological component and a therapist managing the psychotherapeutic component. These providers often work in different settings, communicate infrequently, and have different visibility into the patient's clinical picture.

This article covers how to function effectively as the prescribing component of a combined treatment plan.

---

Setting Up the Treatment Plan

When a new patient presents with a PMAD and is starting both medication and therapy (or medication in addition to existing therapy), clarify:

Who is the therapist? If the patient is not yet connected with a therapist, facilitate this. A referral to a PMH-C certified therapist (Postpartum Support International certification) is the most targeted option. General therapists without perinatal specialization may not use the evidence-based modalities (CBT, IPT, EMDR for birth trauma) that produce best outcomes.

What is the therapy modality? CBT and IPT are the most studied for perinatal depression and anxiety. EMDR is the evidence-based approach for birth trauma/PTSD. If the patient is seeing a therapist who is not using a structured evidence-based approach, this is worth noting.

Communication consent. Obtain a release of information for contact with the therapist early. Brief communication between prescriber and therapist improves coordination and is otherwise impractical.

Timeline alignment. SSRI onset is typically 4 to 6 weeks for full therapeutic effect. Therapy often shows impact more rapidly (some patients notice changes within the first few sessions). Brief communication about timeline expectations helps both providers interpret the clinical picture accurately.

---

What to Communicate to the Therapist

With a release in place, a brief initial communication at treatment start saves time and reduces miscommunication:

"I've started [patient] on [medication] [dose] for [indication]. We are targeting primarily [anxiety/depression/OCD symptoms]. I expect to assess initial response at 4 to 6 weeks. If you observe [specific concerns -- e.g., worsening symptoms in the first 2 weeks, emergence of suicidality, significant functional decline], please reach out. I'll plan to be in touch after the first follow-up appointment."

This is not a clinical summary -- it is a handshake communication that establishes a shared expectation for the treatment arc.

---

Medication Timing and Therapy

The startup period (weeks 0 to 4)

SSRIs and SNRIs take 4 to 6 weeks for full effect. The first 2 weeks often involve side effects (GI disturbance, mild anxiety activation for some patients) without clear symptom benefit. This is a clinically important period because:

• Patients may attribute side effects to the medication making things worse
• Therapists may see patients who are more symptomatic than baseline
• Patients may stop the medication before the therapeutic window is reached

Proactive communication to both the patient and the therapist about the expected startup curve reduces premature discontinuation. Specifically: the first 2 weeks are not the therapeutic effect of the medication; the therapeutic effect typically begins at weeks 3 to 4 and continues to build through week 6 to 8.

Short-term adjunct: A brief course of lorazepam or hydroxyzine for patients with acute anxiety that is impairing function during the startup period is appropriate and should be communicated to the therapist.

The response assessment window (weeks 4 to 8)

At 4 to 6 weeks, assess response. A patient who is not responding to the initial dose may benefit from dose optimization before considering an agent switch.

Dose thresholds for common agents:

• Sertraline: therapeutic range 50 to 200 mg. OCD often requires 150 to 200 mg.
• Escitalopram: 10 to 20 mg. Limited dose-response above 20 mg.
• Fluoxetine: 20 to 60 mg for depression; 60 to 80 mg for OCD.
• Venlafaxine XR: 75 to 225 mg. SNR effect increases meaningfully above 150 mg.

A partial response at a low dose is a titration indication, not an agent failure.

Therapy progress and medication needs

As therapy produces results, medication needs may shift. A patient who has developed strong CBT skills for managing anxiety may be ready to taper anxiolytic medication that was appropriate at treatment onset. A patient who is in active EMDR for birth trauma may have transient increases in distress during trauma processing -- this is not medication failure; it is treatment working. Communication between providers prevents medication escalation in response to planned therapy effects.

---

Recognizing When the Treatment Plan Is Not Working

Inadequate medication response

If a patient has received an adequate medication trial (appropriate dose, 6 to 8 weeks) without sufficient response:

1. Confirm adherence (non-adherence in the perinatal period is common and often not reported)
2. Review the diagnosis -- is the clinical picture consistent with the initial assessment?
3. Consider augmentation (e.g., adding buspirone for anxiety, or augmenting with a second agent)
4. Consider agent switch
5. Consider perinatal psychiatry consultation if first two trials have not produced adequate response

The patient who is not progressing in therapy

As the prescribing provider, your visibility here is limited. Signals to note: the patient continues to report high symptom burden despite adequate medication trial, the therapist has not modified the treatment approach despite lack of progress, or the patient is not attending regularly. A direct conversation with both the patient and a communication to the therapist is appropriate.

When to escalate

Escalation to a higher level of care (IOP, PHP, or inpatient) is warranted when:

• The patient is not safe in the outpatient setting
• Outpatient combined treatment has not produced adequate response after two adequate medication trials
• The functional impairment is severe enough that the patient cannot engage in outpatient therapy
• There is an active safety concern

For guidance on transitioning patients to IOP or PHP, see our article on step-down care from IOP to outpatient.

---

The Prescriber's Role in Breastfeeding Decisions

When a PMAD patient is breastfeeding, medication decisions must account for breastfeeding safety. This is a shared decision with the patient; the therapist may have visibility into the patient's attachment to breastfeeding that the prescriber lacks.

Before prescribing, ask: Is the patient breastfeeding? Does she intend to continue? If medication is being added or changed, is the new agent compatible with breastfeeding?

Brief communication to the therapist about medication changes that affect breastfeeding (e.g., "I've switched her from escitalopram to sertraline for better breastfeeding profile; she should notice minimal transition effects") gives the therapist context for changes the patient may discuss in session.

---